+86-27-65522453 sales@sun-shinechem.com

Cenicriviroc Mesylate

Catalog No.: S510901
Cas No.: 497223-28-6
Purity : 98% Min.
S510901 - Cenicriviroc Mesylate | CAS 497223-28-6

Catalog number : S510901

CAS number : 497223-28-6

分子式 : C42H56N4O7S2

分子量 : 793.05

Iupac 化学名称 : (S,E)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide, mesylate

Smile : O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4.OS(=O)(C)=O

InChiKey : IXPBPUPDRDCRSY-YLZLUMLXSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词Cenicriviroc Mesylate,TAK-652 Mesylate; TBR-652 Mesylate,,TAK652,TAK 652
英文同义词Cenicriviroc Mesylate,TAK-652 Mesylate; TBR-652 Mesylate,TAK652,TAK 652
分子式C42H56N4O7S2
分子量793.05
外观 黄色固体
纯度98% Min.
可溶性可溶于DMSO;不溶于水
存储短期可在0-4度保存,数天至数月;长期可在-20度保存三年。
运输条件可在常温下运输
SmileO=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4.OS(=O)(C)=O
InChiKeyIXPBPUPDRDCRSY-YLZLUMLXSA-N
InChiInChI=1S/C41H52N4O4S.CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2;1-5(2,3)4/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46);1H3,(H,2,3,4)/b34-26+;/t50-;/m0./s1

Cenicriviroc(代号TAK-652,TBR-652)是用于治疗HIV感染的实验候选药物。它由Takeda和Tobira Therapeutics开发。

Cenicriviroc是CCR2和CCR5受体的抑制剂,使其能够作为进入抑制剂起作用,阻止病毒进入人体细胞。抑制CCR2可能具有抗炎作用。

1. Neokosmidis G, Tziomalos K., Role of cenicriviroc in the management of nonalcoholic fatty liver disease.World J Gastroenterol. 2018 Dec 28;24(48):5415-5417. doi: 10.3748/wjg.v24.i48.5415

2.  Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L., APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc. Front Immunol. 2018 Aug 8;9:1839. doi: 10.3389/fimmu.2018.01839. eCollection 2018.

3. D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y., Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 Dec;104(6):1241-1252. doi: 10.1002/JLB.5A0817-328RRR. Epub 2018 Aug 8.


497223-28-6 - Request Bulk Quote

×
497223-28-6 - Request Bulk Quote
Change